Genetic variations in MAGE-A11 predict the risk and survival of renal cell cancer
Shifeng Su, Qi Gu, Aiming Xu, Sipeng Shen, Shouyong Liu, Chao Zhang, Chengkui Miao, Chao Qin, Bianjiang Liu, Zengjun Wang · Journal of Cancer · 2019
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2019
Abstract
Melanoma antigen-A11 (MAGE-A11) is a low-abundance, primate-specific steroid receptor coregulator in normal tissues of the human reproductive tract, which plays an important role in tumorigenesis.Single-nucleotide polymorphisms (SNPs) have been shown to contribute to cancer risk and prognosis.However, the role of SNPs of MAGE-A11 in renal cell carcinoma (RCC) has not been established.Two intronic SNPs (rs6641352 and rs6540341) of MAGE-A11 have been screened to assess their associations with RCC risk and prognosis in a case control study.We found that rs6641352 was associated with RCC susceptibility in the dominant model (TC/CC vs.
TT, adjusted odds ratio = 1.315, 95% confidence interval [CI] = 1.089-1.588)and with survival of RCC in the recessive model (CC vs. TT/TC, adjusted hazard ratio = 3.526, 95% CI = 1.072-11.595).For the SNP rs6540341, individuals with the T allele could have a critically increased risk of RCC (adjusted odds ratio = 1.301, 95% CI = 1.081-1.564,P = 0.005 in the dominant model).However, there was no significant association between rs6540341 and RCC survival.Hence, rs6641352 in MAGE-A11 may contribute to the genetic susceptibility and prognosis for RCC and act as a biomarker for RCC occurrence and prognosis.
Open the resolved locator · 10.7150/jca.32675
Metadata licence: OpenAlex metadata (CC0)